News
Among patients with COPD and type 2 inflammation, investigator-reported emphysema did not change benefits seen with dupilumab ...
California says the sale of 23andMe to a nonprofit formed by the company's former CEO would skirt a state law specifically ...
Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...
SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)--Jun 16, 2025-- ...
Roche/Genentech entered into a Licensing, Development, and Commercialization agreement with Prothena in December 2013 to develop and commercialize monoclonal antibodies targeting aggregated ...
2d
MedPage Today on MSNMonotherapy for CLLThe initial report of monotherapy with the BCL-2 inhibitor venetoclax showed it had durable clinical activity and favorable ...
2d
MedPage Today on MSNBTK Inhibitors for Multiple SclerosisMultiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...
Genentech announced a third round of layoffs, affecting 143 jobs, as part of its strategic workforce adjustments, amid broader job cuts across various sectors in Northern California.
Those adjustments just keep coming. As SFGATE reported, Genentech announced 436 layoffs in April 2024, and 93 more layoffs ...
The study, led from the University of Utah, analyzed 3,286 hospitals across the country, using data from the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey, which ran ...
Genentech is planning cuts on the Peninsula.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results